VRCA Stock Overview
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Verrica Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.56 |
| 52 Week High | US$9.61 |
| 52 Week Low | US$2.86 |
| Beta | 1.83 |
| 1 Month Change | 39.16% |
| 3 Month Change | 81.06% |
| 1 Year Change | 60.67% |
| 3 Year Change | -17.87% |
| 5 Year Change | 7.42% |
| Change since IPO | -45.37% |
Recent News & Updates
Recent updates
Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?
Jan 11
Here's Why We're Not At All Concerned With Verrica Pharmaceuticals' (NASDAQ:VRCA) Cash Burn Situation
Jun 28We're Hopeful That Verrica Pharmaceuticals (NASDAQ:VRCA) Will Use Its Cash Wisely
Feb 05Vectoring Back In On Verrica Pharmaceuticals
Aug 31Verrica Pharmaceuticals reports insider buying
Jul 06Verrica Pharmaceuticals stock slides on proposed share offering
Jun 29Verrica Pharmaceuticals Should Receive Second CRL Today
May 24Auditors Have Doubts About Verrica Pharmaceuticals (NASDAQ:VRCA)
Mar 07Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 06Time To Worry? Analysts Just Downgraded Their Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Outlook
Dec 17FDA extends review period for Verrica Pharmaceuticals' VP-102 NDA
May 28Verrica Pharmaceuticals EPS beats by $0.32
May 07Verrica Pharma refiles US application for lead candidate in infectious skin disease
Dec 23Verrica Pharma receives final FDA minutes regarding NDA resubmission for VP-102 in molluscum
Nov 17Verrica Pharma' VP-102 successful in mid-stage study for genital warts
Nov 10Verrica Pharmaceuticals EPS misses by $0.02
Nov 09Shareholder Returns
| VRCA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 25.0% | 0.6% | 0.6% |
| 1Y | 60.7% | 13.1% | 25.7% |
Return vs Industry: VRCA exceeded the US Pharmaceuticals industry which returned 12.9% over the past year.
Return vs Market: VRCA exceeded the US Market which returned 25.7% over the past year.
Price Volatility
| VRCA volatility | |
|---|---|
| VRCA Average Weekly Movement | 9.2% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: VRCA's share price has been volatile over the past 3 months.
Volatility Over Time: VRCA's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 100 | Ted White | www.verrica.com |
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial.
Verrica Pharmaceuticals Inc. Fundamentals Summary
| VRCA fundamental statistics | |
|---|---|
| Market cap | US$405.54m |
| Earnings (TTM) | -US$80.74m |
| Revenue (TTM) | US$8.91m |
45.5x
P/S Ratio-5.0x
P/E RatioIs VRCA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VRCA income statement (TTM) | |
|---|---|
| Revenue | US$8.91m |
| Cost of Revenue | US$19.53m |
| Gross Profit | -US$10.62m |
| Other Expenses | US$70.12m |
| Earnings | -US$80.74m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.90 |
| Gross Margin | -119.13% |
| Net Profit Margin | -905.83% |
| Debt/Equity Ratio | 2,841.4% |
How did VRCA perform over the long term?
See historical performance and comparison